Navigation Links
Survival Data in FDA Approval for ERBITUX(R) (Cetuximab) Supports use as a Single Agent in Patients with Advanced Colorectal Cancer
Date:10/2/2007

sh occurred in 76-88% of 1373 patients receiving ERBIUTX in clinical trials. Severe acneform rash occurred in 1-17% of patients. Acneform rash usually developed within the first two weeks of therapy and resolved in a majority of the patients after cessation of treatment, although in nearly half, the event continued beyond 28 days. Monitor patients receiving ERBITUX for dermatologic toxicities and infectious sequelae. Sun exposure may exacerbate these effects

In women of childbearing potential, appropriate contraceptive measures must be used during treatment with ERBITUX and for 6 months following the last dose of ERBITUX. If ERBITUX is used during pregnancy or if patients become pregnant while receiving ERBITUX, patients should be apprised of the potential risk for loss of pregnancy or potential hazard to the fetus

Hypomagnesemia occurred in 55% (199/365) of patients receiving ERBITUX and was severe (NCI CTC grades 3 & 4) in 6-17%. The onset of hypomagnesemia and accompanying electrolyte abnormalities occurred days to months after initiation of ERBITUX. Monitor patients periodically for hypomagnesemia, hypocalcemia and hypokalemia, during and for at least 8 weeks following the completion of ERBITUX. Replete electrolytes as necessary

The most serious adverse reactions associated with ERBITUX in mCRC patients are infusion reactions, dermatologic toxicity, sepsis, renal failure, interstitial lung disease, and pulmonary embolus.

The most common adverse reactions with ERBITUX (incidence greater than or equal to 25% in the ERBITUX plus best supportive care arm (BSC)) (n=288) vs. BSC (n=274), respectively, were fatigue (89%, 76%), rash/desquamation (89%, 16%), abdominal pain (59%, 52%), pain-other (51%, 34%), dry skin (49%, 11%), dyspnea (48%, 43%), constipation (46%, 38%), pruritus (40%, 8%), diarrhea (39%, 20%), vomiting (37%, 29%), infection without neutropenia (35%, 17%), headache (33%, 11%), fever (30%, 18%), insomnia (30%, 15%), cough (29%, 19
'/>"/>

SOURCE Bristol-Myers Squibb Company; ImClone Systems Incorporated
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Velcade (bortezomib) for Injection Based Induction Therapy Delivered High Post-Transplant Complete Remission Rate, a Critical Marker for Increased Overall Survival
2. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
3. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
4. Velcade (bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients
5. Velcade (bortezomib) for Injection Survival Data in Front-Line Multiple Myeloma Patients to be Featured at 11th International Myeloma Workshop
6. First single breast cancer study to show significant survival benefit for women switching from tamoxifen to Arimidex
7. Research Documents Scalable Production, Survival Following Engraftment and Positive Impact on Cardiac Function in Infarcted Rats for Gerons Human Embryonic Stem Cell-Based Therapeutic for Heart Failure
8. Anastrozole (Arimidex) Improves Overall Survival in Postmenopausal Women with Early Breast Cancer Receiving Treatment with Tamoxifen
9. Ivivis PEMF Technology Significantly Improves Neuron Survival in Parkinsons Disease Model, Study Finds
10. Synta Presents Results for STA-4783 in Metastatic Melanoma Showing Improvement in Overall Survival
11. Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III Melanoma Demonstrated Significant and Sustained Impact on Relapse-Free Survival
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... July 30, 2015  Lannett Company, Inc. (NYSE: ... at the Canaccord Genuity 35th Annual Growth Conference on ... the InterContinental Boston Hotel.  A webcast ... .  Listeners are encouraged to visit the web site ... the presentation to register, download and install any necessary ...
(Date:7/30/2015)...  Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) today ... at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time) ... 2015 financial results and provide a corporate update. Arena ... Select Market closes that day. The conference ... callers and 914.495.8552 for international callers. Please specify to ...
(Date:7/30/2015)... Ohio, July 30, 2015  Cardinal Health today ... billion, an increase of 20 percent, and non-GAAP ... of $1.00, an increase of 20 percent. Non-GAAP ... On a GAAP basis, operating earnings increased 44 ... continuing operations increased 29 percent to $0.88. ...
Breaking Medicine Technology:Arena Pharmaceuticals to Host Second Quarter 2015 Financial Results and Corporate Update Conference Call and Webcast on Wednesday, August 5 2Arena Pharmaceuticals to Host Second Quarter 2015 Financial Results and Corporate Update Conference Call and Webcast on Wednesday, August 5 3Arena Pharmaceuticals to Host Second Quarter 2015 Financial Results and Corporate Update Conference Call and Webcast on Wednesday, August 5 4Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 2Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 3Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 4Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 5Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 6Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 7Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 8Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 9Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 10Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 11Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 12Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 13Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 14Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 15Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 16Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 17Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 18Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 19Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 20Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 21Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 22Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 23Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 24Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 25Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 26Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 27Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 28Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 29Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 30Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 31Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 32Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 33
... DIEGO, May 4, 2011 Volcano Corporation (NASDAQ: ... precision guided therapy tools designed to enhance the treatment ... signing of a supply agreement with ev3, a Covidien ... Ultrasound ( IVUS) technology for use in ev3,s ...
... Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX ... and gastroenterology markets, today announced first quarter 2011 financial results. ... ended March 31, 2011, net revenue was $10.7 million, up ... grew year-over-year despite a brief, planned halt in shipments of ...
Cached Medicine Technology:Volcano Corporation to Supply Intravascular Ultrasound Technology to Covidien for Integration with Plaque Excision Systems 2Volcano Corporation to Supply Intravascular Ultrasound Technology to Covidien for Integration with Plaque Excision Systems 3Cumberland Pharmaceuticals Reports First Quarter 2011 Financial Results 2Cumberland Pharmaceuticals Reports First Quarter 2011 Financial Results 3Cumberland Pharmaceuticals Reports First Quarter 2011 Financial Results 4Cumberland Pharmaceuticals Reports First Quarter 2011 Financial Results 5Cumberland Pharmaceuticals Reports First Quarter 2011 Financial Results 6Cumberland Pharmaceuticals Reports First Quarter 2011 Financial Results 7Cumberland Pharmaceuticals Reports First Quarter 2011 Financial Results 8Cumberland Pharmaceuticals Reports First Quarter 2011 Financial Results 9Cumberland Pharmaceuticals Reports First Quarter 2011 Financial Results 10
(Date:7/30/2015)... ... July 30, 2015 , ... Zaca Life ... the go. With no water needed, the refreshing berry-flavored tablets are the perfect ... get the natural ingredients that may help with body detoxification, protection and hydration,” ...
(Date:7/30/2015)... Angeles, CA (PRWEB) , ... July 30, 2015 , ... ... cars on an upcoming dedicated web site. As discussed in a June 8, 2015 ... the minor collisions reported so far have been caused by its computer-driven cars, which ...
(Date:7/30/2015)... , ... July 30, 2015 ... ... a video, “Beachside Nursing Center,” to announce its position as one of ... Beachside's administrator and staff members support the CMS rating system, which monitors ...
(Date:7/30/2015)... ... 2015 , ... Zejax is a New Way of Training ... , World renown body weight trainer, Paul Ziachik, announces today that he ... a person’s training capability. , The American College of Sports Medicine states that ...
(Date:7/30/2015)... ... 30, 2015 , ... Boston Web Marketing is ... Google Partners is the platform for search marketing agencies to communicate with the ... necessary to run successful search marketing campaigns. Google Partners also affords businesses the ...
Breaking Medicine News(10 mins):Health News:Zaca Life Introduces Recovery Chewable Packets with Setria® Glutathione and Sustamine® L-Alanyl-L-Glutamine 2Health News:Zaca Life Introduces Recovery Chewable Packets with Setria® Glutathione and Sustamine® L-Alanyl-L-Glutamine 3Health News:Zaca Life Introduces Recovery Chewable Packets with Setria® Glutathione and Sustamine® L-Alanyl-L-Glutamine 4Health News:New Google Policy on Reporting Driverless Auto Accidents Points Out Growing Complexity of Personal Injury Law in the 21st Century, Says Law Offices of Burg and Brock 2Health News:New Google Policy on Reporting Driverless Auto Accidents Points Out Growing Complexity of Personal Injury Law in the 21st Century, Says Law Offices of Burg and Brock 3Health News:Beachside Nursing Center Releases New Video 2Health News:Zejax is a Revolutionary New Way of BodyWeight Training Without Weights 2Health News:Boston Web Marketing Attends Google Partners All-Stars Summit 2
... Safety Project Report Makes Recommendations for System in Critical Need ... Nov. 17 Weaknesses in food safety policy, organization and ... Saintpaul, according to a report released today by the Produce ... at Georgetown University . , ...
... MYL ) today announced that its subsidiary, Mylan ... Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) ... , Fluoxetine Capsules, indicated for ... version of Eli Lilly,s Sarafem(R) Pulvules(R) Capsules. This product had ...
... procedure in which her stem cells were combined with ... , , TUESDAY, Nov. 18 (HealthDay News) -- In a ... undergone the first transplantation of a breathing passage fashioned ... researchers report. , As of now, the woman, Claudia ...
... as Chairman, Tony Strange Appointed to CEO position and Will ... , MELVILLE, N.Y., Nov. 18 /PRNewswire-FirstCall/ ... ), a leading provider of comprehensive home health services, announced ... succession plan. Effective January 1, 2009, Tony Strange will ...
... and Policy Center (NLPC), a plaintiff in the successful 1993 ... Clinton,s health care task force, today criticized Barack Obama for ... , According to NLPC President Peter ... General. His track record is not one of independence or ...
... mechanisms, scientists show , , TUESDAY, Nov. 18 (HealthDay News) ... mechanisms, according to a Washington University study that challenges ... version of the body,s response to pain. , This ... itching and pain. , Zhou-Feng Chen, of Washington University,s ...
Cached Medicine News:Health News:Salmonella Saintpaul Outbreak Exposes Food Safety Weaknesses 2Health News:Salmonella Saintpaul Outbreak Exposes Food Safety Weaknesses 3Health News:Airway Transplant Aided by Stem Cells a Medical First 2Health News:Airway Transplant Aided by Stem Cells a Medical First 3Health News:Gentiva Health Services Confirms Management Succession 2Health News:Gentiva Health Services Confirms Management Succession 3Health News:Gentiva Health Services Confirms Management Succession 4Health News:NLPC Criticizes Obama's Choice of Eric Holder for Attorney General Because of Role in Health Care Task Force Cover-Up 2Health News:Itching Not a Less Intense Form of Pain 2
... up to 10 inches/ 25 cm thinner than other ... Allegra X-22 Series is the space-saving multipurpose solution for ... / 46 cm wide • 11 Rotor Library • ... ways to Spin 1.5 mL & PCR+ Tubes: ...
... is up to 10 inches/ 25 cm thinner than ... the Allegra X-22 Series is the space-saving multipurpose solution ... inches / 46 cm wide • 11 Rotor Library ... different ways to Spin 1.5 mL & PCR+ Tubes: ...
... centrifuges offer high-volume versatility along with a ... them ideal for a wide variety of ... Four- or six-place sealed swinging bucket rotor, ... offered , Lare capacity (4 x 750 ...
... Multipurpose high performance centrifuge designed to accommodate ... devices is refrigerated for heat labile samples. ... include refrigerated capability with automatic quick cooling ... < 7 min, no maintenance brushless motor, ...
Medicine Products: